Latest / Breaking News To Trading Moves
Gilead’s $7.8B Arcellx Acquisition: Scaling CAR-T Oncology Dominance
Gilead to acquire Arcellx for up to $7.8B
$GILD (Gilead Sciences) is buying cancer therapy developer $ACLX (Arcellx) for up to $7.8B, doubling down on CAR-T in multiple myeloma and taking fuller control of their partnered therapy anito-cel.
What happened
Gilead will pay $115 per share in cash for Arcellx, a big premium to the prior close, and there’s also a contingent $5 per share tied to anito-cel sales milestones.
The key asset is anito-cel, a CAR-T therapy for multiple myeloma that’s under FDA review, with a decision expected by December 23, 2026.
Strategically, this is Gilead leaning…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.